Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show
Treatment with Xtandi (enzalutamide) significantly extends the lives of men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), according to final data from a Phase 3 clinical trial. Developed by Pfizer and Astellas Pharma, Xtandi is an oral hormone therapy that works by blocking the interaction between male hormones and their receptors in cancer cells. Since this interaction can stimulate prostate cancer growth, Xtandi is expected to halt cancer progression in these patients. The therapy is currently approved in the U.S. and in Europe for the treatment of three types of advanced prostate cancer: high-risk non-metastatic CRPC, metastatic CRPC, and metastatic castration-sensitive prostate cancer (mCSPC). Xtandi’s approval for treating men with high-risk non-metastatic CRPC was based on positive data from the Phase 3 PROSPER clinical trial (NCT02003924). PROSPER was designed to assess whether adding Xtandi to standard
Subscribe or to access all post and page content.